Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition
Mehri Monavarian, Resha Rajkarnikar, Emily Faith Page, Asha Kumari, Liz Quintero Macias, Felipe Massicano, Nam Y. Lee, Sarthak Sahoo, Nadine Hempel, Mohit Kumar Jolly, Lara Ianov, Elizabeth Worthey, Abhyudai Singh, Igor B. Roninson, Eugenia V. Broude, Mengqian Chen, Karthikeyan Mythreye
Mehri Monavarian, Resha Rajkarnikar, Emily Faith Page, Asha Kumari, Liz Quintero Macias, Felipe Massicano, Nam Y. Lee, Sarthak Sahoo, Nadine Hempel, Mohit Kumar Jolly, Lara Ianov, Elizabeth Worthey, Abhyudai Singh, Igor B. Roninson, Eugenia V. Broude, Mengqian Chen, Karthikeyan Mythreye
View: Text | PDF
Research Article Cell biology Oncology

Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition

  • Text
  • PDF
Abstract

Anoikis resistance, or evasion of cell death triggered by matrix detachment, is a hallmark of cancer cell survival and metastasis. We showed that repeated exposure to suspension stress followed by recovery under attached conditions leads to development of anoikis resistance. The acquisition of anoikis resistance was associated with enhanced invasion, chemoresistance, and immune evasion in vitro and distant metastasis in vivo. This acquired anoikis resistance was not genetic, persisting for a finite duration without detachment stress, but was sensitive to CDK8/19 mediator kinase inhibition that could also reverse anoikis resistance. Transcriptomic analysis revealed that CDK8/19 kinase inhibition induces bidirectional transcriptional changes in both sensitive and resistant cells, disrupting the balanced reprogramming required for anoikis adaptation and resistance by reversing some resistance-associated pathways and enhancing others. Both anoikis resistance and in vivo metastatic growth of ovarian cancers are sensitive to CDK8/19 inhibition, thereby providing a therapeutic opportunity to both prevent and suppress ovarian cancer metastasis.

Authors

Mehri Monavarian, Resha Rajkarnikar, Emily Faith Page, Asha Kumari, Liz Quintero Macias, Felipe Massicano, Nam Y. Lee, Sarthak Sahoo, Nadine Hempel, Mohit Kumar Jolly, Lara Ianov, Elizabeth Worthey, Abhyudai Singh, Igor B. Roninson, Eugenia V. Broude, Mengqian Chen, Karthikeyan Mythreye

×

Figure 6

Adapted AnR cancer cells evade killing by cytotoxic T cells.

Options: View larger image (or click on image) Download as PowerPoint
Adapted AnR cancer cells evade killing by cytotoxic T cells.
(A) NES for...
(A) NES for inflammatory response vs. apoptosis hallmarks in OV90 cells across passages P0–P7; n = 3. (B) qRT-PCR of HLAA, B, and C in AnS (P0, P1) and AnR (P6, P7) OV90 cells; n = 3. (C) Representative Western blot for TAP1 and MHCI in AnS and AnR cells; quantitation normalized to β-actin below (n = 2). (D) Schematic (left) and percent viability (right) of OV90 and CAOV3 cells after coculture with activated human CD8+ T cells (24–48 hours for OV90, 24 hours for CAOV3); n = 3. (E) Cleaved caspase-3 immunofluorescence in OV90 and CAOV3 cells after CD8+ T cell coculture (48 hours for OV90, 12 hours for CAOV3); scale bar: 50 μm; n = 3. *P < 0.05; **P < 0.01; ***P < 0.001; by 2-way ANOVA with Tukey’s test (B, D-OV90), 1-way ANOVA with Tukey’s test (D-CAOV3, E). Data are mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts